CoMind, a British neurological HealthTech startup,
has raised €51 million in its latest funding round,
led by Plural, with participation from longstanding backers including LocalGlobe, Latitude, Octopus Ventures, Crane, Angelini Ventures, and Lord David Prior.
This investment will support the company's US clinical trials, regulatory approval journey, and manufacturing partnerships, as CoMind prepares to scale globally.
The funding round stands out as one of the largest in European neuro-device funding this year, underscoring both investor confidence in non-invasive brain technologies and the UK's growing role in the continent's HealthTech innovation landscape. The company has secured
over €85 million in total funding as it scales its neuromonitoring technology that measures critical brain parameters without the need for drilling into the skull.
Founded in 2018 by 25-year-old
James Dacombe,
CoMind is aiming to revolutionise how clinicians monitor the brain – entirely non-invasively. Its flagship product, CoMind One, utilises low-power laser light to measure critical brain parameters such as cerebral blood flow and intracranial pressure without the need for drilling into the skull. The device marks a leap in brain monitoring, especially for use in intensive care units, surgical theatres, and neuro-critical settings.
CoMind is now aiming to get regulatory approval for its technology within two years, at which point it will begin selling to the huge ICU market in the US.
Taavet Hinrikus, Partner at Plural, comments: "The company's technology has the potential to dramatically improve how we monitor our brains, giving doctors better information and more choices for treating patients, building out a whole extra market by providing a far more affordable and safe alternative to existing solutions.
This makes CoMind a classic Plural investment: a startup that can make a huge global impact, built in Europe."For more information, please visit
Plural Features.
